A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis Followed by Extended Treatment With Open-label BAF312.

Trial Profile

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis Followed by Extended Treatment With Open-label BAF312.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Oct 2017

At a glance

  • Drugs Siponimod (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms EXPAND
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 27 Jun 2017 Status changed from recruiting to active, no longer recruiting ,as per results published at the 3rd Congress of the European Academy of Neurology.
    • 27 Jun 2017 Results assessing efficacy, presented at the 3rd Congress of the European Academy of Neurology.
    • 27 Jun 2017 Safety and tolerability results presented at the 3rd Congress of the European Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top